Effect of desiccating environmental stress versus systemic muscarinic AChR blockade on dry eye immunopathogenesis

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 4, 2013, Pages 2457-2464

  Chen, Yihe ^a   Chauhan, Sunil K ^a   Lee, Hyun Soo ^a   Stevenson, William ^a   Schaumburg, Chris S ^b   Sadrai, Zahra ^a   Saban, Daniel R ^a   Kodati, Shilpa ^a   Stern, Michael E ^b   Dana, Reza ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

CD4th T cellsdry eye disease; CD4th T cells; Controlled environment chamber; Dry eye disease; Scopolamine

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRY EYE; ENVIRONMENTAL STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LACRIMAL APPARATUS; LYMPH NODES; MICE; MICE, INBRED C57BL; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC; SCOPOLAMINE HYDROBROMIDE; STRESS, PHYSIOLOGICAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84875960281     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11121     Document Type: Article

References (31)

1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
2. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009;127:763-768.
3. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and nonSjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
4. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T-cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
5. El Annan J, Chauhan SK, Ecoiffier T, Zhang Q, Saban DR, Dana R. Characterization of effector T-cells in dry eye disease. Invest Ophthalmol Vis Sci. 2009;50:3802-3807.
6. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182:1247-1252.
7. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-253.
8. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002; 43:632-638.
9. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219-225.
10. Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46:2766-2771.
11. Dartt DA. Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res. 2009;28:155-177.
12. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit. 2005;27:655-665.
13. Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? Arthritis Rheum. 2005;52:2984-2995.
14. Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of nonneuronal acetylcholine: expression of an independent, nonneuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J Pharmacol Sci. 2008;106:186-192.
15. Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci. 2003;74:675-696.
16. 2+ oscillation and c-fos gene expression induced via muscarinic acetylcholine receptor in human leukemic T-and B-cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:14-21.
17. Nomura J, Hosoi T, Okuma Y, Nomura Y. The presence and functions of muscarinic receptors in human T-cells: the involvement in IL-2 and IL-2 receptor system. Life Sci. 2003; 72:2121-2126.
18. Razani-Boroujerdi S, Behl M, Hahn FF, Pena-Philippides JC, Hutt J, Sopori M. Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol. 2008;194:83-88.
19. Arzt ES, Fernández-Castelo S, Diaz A, Finkielman S, Nahmod VE. The muscarinic agonist pilocarpine inhibits DNA and interferon-gamma synthesis in peripheral blood mononuclear cells. Int J Immunopharmacol. 1989;11:275-281.
20. Fujii YX, Tashiro A, Arimoto K, et al. Diminished antigenspecific IgG1 and interleukin-6 production and acetylcholinesterase expression in combined M1 and M5 muscarinic acetylcholine receptor knockout mice. J Neuroimmunol. 2007;188:80-85.
21. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21: 221-232.
22. Hicks DG, Kushner L, McCarthy K. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling. J Natl Cancer Inst Monogr. 2011;42:43-45.
23. Subcommittee of the International Dry Eye Workshop. The definition and classification of dry eye disease: report of the Definition and Classification. Ocul Surf. 2007;5:75-92.
24. Pitcher JD 3rd, De Paiva CS, Pelegrino FS. et al. Pharmacological cholinergic blockade stimulates inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal gland. Invest Ophthalmol Vis Sci. 2011;52:3221-3227.
25. Qian J, Galitovskiy V, Chernyavsky AI, Marchenko S, Grando SA. Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of näi{dotless}ve CD4 T-cells toward the Th1, Th2 and Th17 lineages. Genes Immun. 2011; 12:222-230.
26. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells. Nature. 2006;441:235-238.
27. Chaudhry A, Rudra, D, Treuting, P, et al. CD4+ regulatory Tcells control TH17 responses in a Stat3-dependent manner. Science. 2009;326:986-991.
28. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol. 2009;183:6681-6688.
29. + regulatory T-cells in mice in vitro. J Pharmacol Exp Ther. 2010;335:553-561.
30. Chauhan SK, Dana R. Role of Th17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol. 2009;2:375-376.
31. Nemet A, Belkin M, Rosner M. Transplantation of newborn lacrimal gland cells in a rat model of reduced tear secretion. Isr Med Assoc J. 2007;9:94-98.